Multiple Myeloma

Multiple Myeloma (MM) is a neoplasm of plasma cells and is the second most common hematological malignancy, accounting for 1% of all malignancies. It approximately affects 1-5/100000 individuals worldwide each year, primarily affecting the elderly population with a median age of 70 years. The disease is characterized by the presence of a monoclonal protein in serum or urine and increased plasma cells in the bone marrow. MM evolves from a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS).

Chemotherapy consisting of melphalan and prednisolone has been the main therapy for MM, with a response rate of 50%. Other aggressive therapies such as VBMCP have resulted in superior response rates but no benefit to survival. Autologous stem cell transplantation can improve response rates to 75-90% and results in remission rates between 20-40%.

5:13
Exciting new treatments in myeloma
Xavier Leleu
2:42
The IFM 2012-03 trial: what will the next step be?
Xavier Leleu
1:49
Pros and cons of increasing CD38 expression
Torben Plesner
1:05
Daratumumab: no evidence of disease after treatment?
Torben Plesner
3:03
PDL1 and CD38 antigen expression in NSCLC
Torben Plesner
3:27
Case study: daratumumab in a relapsed patient
Saad Usmani
3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau
3:33
Using cell mass to determine response to treatment: A possible cure?
Nikhil Munshi
2:16
What novel technologies are available for myeloma?
Nikhil Munshi
1:03
What is induction therapy for autologous stem cell transplanation?
Michele Cavo
4:59
Conflicting results of the EMN02 and staMINA trials
Michele Cavo
2:50
Current standard of care for patients who are eligible for autologous stem cell transplantation
Michele Cavo
1:21
Highlights on interesting data presented at COMy 2017
Meletios Dimopoulos
1:31
How effective are current drug treatments for patients with myeloma kidney disease?
Meletios Dimopoulos
1:56
Effective antibody therapy and updates from the POLLUX and CASTER trials at IMW
Meletios Dimopoulos
5:23
The risk of skeletal adverse events with zoledronic acid
Heinz Ludwig
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals